

Henry Ford Health

## Henry Ford Health Scholarly Commons

---

Dermatology Articles

Dermatology

---

8-3-2022

### Dermatological considerations and culturally sensitive recommendations for women who wear the hijab

Rafey Rehman

Henry Ford Health, rrehman1@hfhs.org

Mahfujul Haque

Marissa Ceresnie

Henry Ford Health, mceresn1@hfhs.org

Iltefat H. Hamzavi

Henry Ford Health, ihamzav1@hfhs.org

Fatima Fahs

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/dermatology\\_articles](https://scholarlycommons.henryford.com/dermatology_articles)

---

#### Recommended Citation

Rehman R, Haque M, Ceresnie M, Hamzavi IH, Fahs F, and Mohammad TF. Dermatological considerations and culturally sensitive recommendations for women who wear the hijab. Br J Dermatol 2022.

This Article is brought to you for free and open access by the Dermatology at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Dermatology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

---

## Authors

Rafey Rehman, Mahfujul Haque, Marissa Ceresnie, Iltefat H. Hamzavi, Fatima Fahs, and Tasneem F. Mohammad

# Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery

Jessica G. Labadie, MD; Sarah A. Ibrahim, MD; Brandon Worley, MD; Bianca Y. Kang, MD; Uros Rakita, MD, MSc; Sarah Rigali, BS; Kenneth A. Arndt, MD; Eric Bernstein, MD, MSE; Jeremy A. Brauer, MD; Sunandana Chandra, MD; Aashish Didwania, MD; Catherine DiGiorgio, MD; Mattias Donelan, MD; Jeffrey S. Dover, MD; Hassan Galadari, MD; Roy G. Geronemus, MD; Mitchel P. Goldman, MD; Merete Haedersdal, MD, PhD, DMSc; George Hruza, MD, MBA; Omar A. Ibrahim, MD, PhD; Arielle Kauvar, MD; Kristen M. Kelly, MD; Andrew C. Krakowski, MD; Rachel Miest, MD; Jeffrey S. Orringer, MD; David M. Ozog, MD; E. Victor Ross, MD; Peter R. Shumaker, MD; Joseph F. Sobanko, MD; Kathleen Suozzi, MD; Mark B. Taylor, MD; Joyce M. C. Teng, MD, PhD; Nathan S. Uebelhoefer, DO; Jill Waibel, MD; Molly Wanner, MD; Ina Ratchev, BSN, RN; Rachel E. Christensen, BS; Emily Poon, PhD; Corinne H. Miller, MLIS; Murad Alam, MD, MSCI, MBA

 [Supplemental content](#)

**IMPORTANCE** Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD.

**OBJECTIVE** To develop recommendations for the safe and effective use of LADD.

**EVIDENCE REVIEW** A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved.

**FINDINGS** Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents ( $\geq 12$  years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline's 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections.

**CONCLUSIONS AND RELEVANCE** This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Murad Alam, MD, MSCI, MBA, Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 N Saint Clair, Ste 1600, Chicago, IL 60611 ([m-alam@northwestern.edu](mailto:m-alam@northwestern.edu)).

JAMA Dermatol. doi:10.1001/jamadermatol.2022.3234  
Published online August 17, 2022.

The protective barrier provided by the stratum corneum limits transcutaneous drug bioavailability, which may be as low as 1% to 5%.<sup>1</sup> Recently, there has been interest in using laser- and energy-based devices to improve transcutaneous absorption. In particular, laser-assisted drug delivery (LADD) may increase drug efficacy without increasing systemic adverse events. Since LADD was first reported in 1987,<sup>2</sup> the technique has rapidly evolved. One development was the introduction of fractional photothermolysis, which creates microscopic, vertical channels of ablation surrounded by layers of coagulated tissue.<sup>2-4</sup> Both ablative fractional (AF) and nonablative fractional (NAF) devices have been used with LADD.<sup>5-7</sup> Laser-assisted drug delivery has been associated with various indications, ranging from epidermal analgesia to treatment of nonmelanoma skin cancer. Interest in the clinical applications of LADD among dermatologists has substantially grown during the past decade as clinicians and patients increasingly seek effective, directed, lower-risk interventions for indications that traditionally required higher doses of topical or systemic medication. Given the rapidly expanding collection of clinical research assessing the efficacy and safety of LADD, this technology is likely to be adopted as a common tool across dermatology.

To our knowledge, there are presently no evidence-based clinical practice guidelines for LADD. The objective of this clinical practice guideline was to delineate applications of LADD and offer recommendations for safe and effective use.

## Methods

This study was approved by the Northwestern University Institutional Review Board (STU00097285). Informed consent was not required because the study used only previously published and publicly available data. Reporting was in accordance with the Appraisal of Guidelines for Research & Evaluation II (AGREE II) guidelines.

### Guideline Questions

This clinical practice guideline was developed to address the following clinical questions:

- I. What are the indications and contraindications for LADD?
- II. What are the most important parameters to report for LADD?
- III. How can drug delivery be enhanced with LADD?
- IV. What are the important safety considerations for LADD?
- V. Is prophylaxis (eg, for bacterial, viral, and fungal infection) required for LADD, and if so, in which circumstances?

### Guideline Development Process

A multidisciplinary panel of expert stakeholders representing dermatology, pediatric dermatology, hematology and oncology, internal medicine, and plastic surgery was assembled based on publication history (including prior publication of guidelines related to laser- or energy-based devices), clinical expertise, peer nomination, and recognition as thought leaders in related areas of research.

The results of a systematic review (available in eMethods 1 in the Supplement) and panel deliberations were used to develop a long list of items related to LADD.<sup>8-10</sup> Then this list was critically evaluated and refined through 2 rounds of Delphi surveys and 2 virtual consensus meetings, with all panel members as Delphi participants (eTable 1 and eMethods 2 in the Supplement).<sup>11,12</sup>

## Key Points

**Question** Which best practices are associated with the safe and effective use of laser-assisted drug delivery (LADD)?

**Findings** This systematic review of 54 studies of LADD informed a multidisciplinary panel of experts and patient representatives who used a Delphi consensus process to develop and refine a guideline for its safe and effective use. The 15 recommendations address 5 areas: indications and contraindications, parameters to report, optimization of drug delivery, safety considerations, and antimicrobial prophylaxis.

**Meaning** This clinical practice guideline provides a current framework to clinicians for the safe and effective use of LADD in various medical and cosmetic settings.

In accordance with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, recommendations were categorized into 2 types: (1) strong recommendations (eg, based on randomized clinical trials with low risk of bias, consistency in results, and without publication bias), signified by the statement "we recommend"; and (2) conditional recommendations (eg, based on lower quality studies or observational studies, and in which variations in care may be more acceptable), signified by the statement "we suggest."

## Results

In total, 48 published studies of AF LADD met inclusion criteria (eFigure in the Supplement): 4 cosmetic studies,<sup>13-16</sup> 21 oncologic,<sup>17-37</sup> and 23 medical (not cosmetic/oncologic).<sup>38-60</sup> In addition, 6 publications of NAF LADD<sup>61-66</sup> were included at the request of the expert panel, for a total of 54 studies.

Studies varied in quality and were generally small, single-center, randomized clinical trials. For certain topics related to LADD, the evidence was of sufficient quality but limited quantity. In these cases, recommendations were based primarily on consensus of expert opinion and in accordance with the Institute of Medicine standards for developing trustworthy clinical practice guidelines.<sup>67</sup> Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk (eTable 2 in the Supplement).

Delphi surveys were conducted in July to December 2020. The first Delphi survey was completed by 30 participants, and the second, by 29 (97% retention). Demographic characteristics of participants are shown in Table 1. Overall, 308 items were presented in the first round, during which 9 additional items were proposed by the Delphi participants. In the second round, 317 items or subparts were presented for rating, and 201 (63.4%) met provisional inclusion criteria. Of these 201 items, 107 were included solely to facilitate discussion, 17 to explore future directions in LADD research, and the remaining 77 as potential actionable items that could become additional recommendations. After an iterative review by a committee of the whole comprised of all Delphi participants and select research personnel, the 77 actionable items were combined into 15 final recommendations (similar items were grouped together). The final recommendations were reviewed by patient-members.

Table 1. Demographic Characteristics of the 30 Delphi Participants

Characteristic	Participants, No. (%)
Medical specialty	
Internal medicine	1 (3.3)
Dermatology	26 (86.7)
Pediatric dermatology	1 (3.3)
Plastic and reconstructive surgery	1 (3.3)
Oncology	1 (3.3)
Country represented	
Denmark	1 (3.3)
United Arab Emirates	1 (3.3)
US	28 (93.3)
Sex	
Female	9 (30.0)
Male	21 (70.0)

### Disclaimer

These guidelines are provided to assist with clinical decision-making but are not a standard of care. Based on patient- and clinician-specific considerations, treating physicians may select courses of action other than those suggested. The panel and the authors assume no responsibility and make no warranty regarding the information provided.

### Final Recommendations for Use of LADD

These 15 recommendations organized into 5 categories were found to be associated with the safe and effective use of LADD. Table 2 provides a summarized list along with GRADE ratings.

#### I. Indications and Contraindications

**Recommendation 1.** We recommend the use of LADD in adults and adolescents with all Fitzpatrick skin types (level of evidence: moderate; recommendation: strong). | Laser-assisted drug delivery is considered to be safe for both adults ( $\geq 18$  years) and adolescents (12 to  $<18$  years); most studies referenced only transient laser-related adverse effects (eg, pain, erythema, crusting), and there were few reports of posttreatment infection.<sup>15</sup> Although LADD has also been used in children, often for analgesia or the treatment of scars, there is considerably less data for this population compared with adults.<sup>38,47</sup> If LADD is performed in children, it should be done so with caution because the safety margin is narrower given their reduced body surface area.

**Recommendation 2.** We suggest that LADD may be safely used in patients with immunosuppression disorders (level of evidence: low; recommendation: conditional). | There are few published studies of LADD in patients who are immunosuppressed, but there have been no reported serious adverse events in this population.<sup>19,26,68</sup> The expert panel determined that LADD is likely safe to use in patients who are immunosuppressed, but that additional research is needed in this population.

**Recommendation 3.** We recommend the use of LADD for the treatment of actinic keratoses, actinic cheilitis, and cutaneous squamous cell carcinoma in situ (level of evidence: moderate; recommendation: strong). | Although there are many indications for LADD as identified through the systematic review and as reported by members

of the expert panel from their own clinical experience (Table 3), there was sufficient evidence to strongly recommend that LADD is safe and effective for the treatment of actinic keratoses,<sup>17-37</sup> actinic cheilitis,<sup>33</sup> and cutaneous squamous cell carcinoma in situ.<sup>61,62</sup> In general, it was found that LADD is most effective for treating these indications, with this typically performed with laser followed by photodynamic therapy (PDT). Additional research is needed to determine the efficacy and safety of LADD with PDT for deeper or more nodular lesions. Pretreatment with AFL before PDT is preferred over pretreatment with NAFL. Two AFL modalities were reported: erbium-doped yttrium aluminium garnet laser (Er:YAG) and carbon dioxide (CO<sub>2</sub>) laser. There were no randomized clinical trials comparing these 2 modalities, and it was the opinion of the expert panel that either Er:YAG or CO<sub>2</sub> lasers may be appropriate. Regarding PDT, either methylaminolevulinic acid or aminolevulinic acid may be utilized.

**Recommendation 4.** We suggest the use of LADD for the treatment of hypertrophic scars and keloids (level of evidence: low; recommendation: conditional). | With CO<sub>2</sub> or Er:YAG lasers, AF LADD is likely a safe and effective treatment for hypertrophic or keloid scars caused by burns, traumatic wounds, and vaccinations.<sup>46-51,65</sup> Recommended topical agents include 5-fluorouracil and corticosteroids (eg, ointment, cream, or aqueous solution); verapamil hydrochloride may also be considered. Multiple treatments, often at 1-month intervals, are often required to attain the desired clinical result.<sup>46,49</sup> Patients tend to tolerate these treatments well, although reported adverse events include increased scar telangiectasia, postinflammatory hyperpigmentation, and transient treatment-related effects such as pain, burning sensation, and edema.<sup>16,70</sup>

**Recommendation 5.** We recommend the use of LADD for epidermal and dermal analgesia if there is sufficient time for application (level of evidence: moderate; recommendation: strong). | In general, a single treatment with AFL (Er:YAG or CO<sub>2</sub>) followed by 5 to 15 minutes of topical anesthetic under occlusion has been associated with significant pain reduction following skin procedures, such as percutaneous procedures, in both pediatric and adult patients. The topical anesthetic agents recommended include 4% tetracaine in benzoyl alcohol and topical lidocaine without epinephrine. Higher density settings provide more effective anesthesia compared with lower density, regardless of the laser modality used, and are typically well-tolerated by patients. Laser-assisted analgesia may be particularly useful in patients undergoing multiple procedures, especially children or others less likely to tolerate pain. The laser surgeon should not exceed the recommended dosing for intralesional injection of the delivered drug.<sup>38-45</sup>

**Recommendation 6.** We recommend LADD be deferred in patients with known allergy to the drug being delivered, active local skin infection, or who have an underlying medical problem or enzyme abnormality if the drug is at risk of worsening the abnormality (level of evidence: moderate; recommendation: strong). | Laser-assisted drug delivery should not be used in patients with a known allergy to the drug, in patients with active infection at the treatment site, or in patients with an underlying medical problem that would be exacerbated by the drug (eg, dihydropyrimidine dehydrogenase deficiency for 5-fluorouracil). Also, laser surgery is relatively contrain-

Table 2. Summary of Recommendations for Laser-Assisted Drug Delivery (LADD)

Category and recommendation	GRADE rating	
	Evidence <sup>a</sup>	Strength <sup>b</sup>
<b>Indications and contraindications</b>		
We recommend the use of LADD in adults (≥18 y) and adolescents (≥12 to <18 y) with all Fitzpatrick skin types.	Moderate	Strong
We suggest that LADD may be safely used in immunosuppressed patients.	Low	Conditional
We recommend the use of LADD for the treatment of actinic keratoses, actinic cheilitis, and cutaneous squamous cell carcinoma in situ.	Moderate	Strong
We suggest the use of LADD for the treatment of hypertrophic scars and keloids.	Low	Conditional
We recommend the use of LADD for epidermal and dermal analgesia if there is sufficient time for application.	Moderate	Strong
We recommend LADD be deferred in patients with known allergy to the drug being delivered, active local skin infection, or who have an underlying medical problem or enzyme abnormality if the drug is at risk of worsening this abnormality.	Moderate	Strong
<b>Parameters to report</b>		
We recommend that the following parameters be reported when performing AF and NAF LADD: fluence/channel depth, density/surface area, spot size, incubation time (time between laser delivery and medicine application), number of passes, and total volume and type of formulation of medication applied.	Moderate	Strong
<b>Optimization of drug delivery</b>		
We suggest that drug delivery via LADD may be increased by using heat, pressure, occlusion, and/or low viscosity drug formulations.	Low	Conditional
We suggest that AF laser settings be selected to ensure that the expected channel diameter is greater than the diameter of the particle being delivered.	Low	Conditional
We suggest that cold, non-hollow bore microneedling (without heat or radiofrequency) or radiofrequency microneedling may be alternative modalities to laser for drug delivery.	Low	Conditional
<b>Safety considerations</b>		
We recommend that physicians using LADD appreciate that there is a certain unpredictability of response and tissue levels of drug owing to variable pharmacokinetics.	Moderate	Strong
We recommend that physicians using LADD be cautious that systemic adverse effects owing to inadvertent systemic delivery of medications are a possibility.	Moderate	Strong
We recommend LADD be performed with appropriate eye protection (appropriate for the laser platform), surgical masks, and gloves (level of evidence: moderate; recommendation: strong), and suggest a smoke evacuator be used, particularly with AF devices (level of evidence: low; recommendation: conditional).	Low	Conditional
We suggest LADD only be used with medication formulations approved by a national regulatory authority for parenteral injection.	Low	Conditional
<b>Prophylaxis for bacterial, viral, and fungal infections</b>		
We suggest the following prophylaxis regimens for AF and NAF LADD in otherwise healthy adult, pediatric, and patients who are immunosuppressed: (1) antibiotic prophylaxis is <i>not</i> recommended when treating areas other than where wound healing might be impaired (eg, genitalia, lower legs); (2) antiviral prophylaxis is recommended when LADD is used on the face or genitalia; and (3) antifungal prophylaxis is <i>not</i> recommended.	Low	Conditional

Abbreviations: AF, ablative fractional; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NAF, nonablative fractional.

<sup>a</sup> Quality of evidence was assessed in accordance with GRADE methodology and rated from 1-4 as very low, low, moderate, or high.

<sup>b</sup> The strength of each recommendation was assessed in accordance with GRADE methodology and rated as 1 (strong) or 2 (conditional).

icated in women who are pregnant or breastfeeding. We suggest that LADD also be relatively contraindicated in women who are pregnant or breastfeeding. That being said, while specific medications may not be appropriate in this context, the use of laser to facilitate delivery into the skin likely does not increase risk.

## II. Parameters to Report

**Recommendation 7.** We recommend that the following parameters be reported when performing AF and NAF LADD: fluence/channel depth, density/surface area, spot size, incubation time (time between laser delivery and medicine application), number of passes, and total volume and type of formulation of medication applied (level of evidence: moderate; recommendation: strong). | Laser surgeons should adjust the standard AFL and NAFL parameters (eg, fluence/channel depth, density/surface area, spot size, incubation time, number of passes, and total volume and type of formulation of medication applied) accordingly based on the device being used, the condition being treated, and the depth of the skin lesion.<sup>70-76</sup> While higher fluences can create deeper laser channels, depth does not necessarily

improve absorption. In addition, higher fluences deliver more heat to the skin, increasing the risk of local adverse events such as pain, burns, and scarring. There may also be an increased likelihood of these adverse events with increased density and number of passes. When performing LADD, the laser surgeon should consider that densities greater than 5% may not offer further improvement in cutaneous drug concentrations or treatment efficacy, and that the risks of treatment-related adverse events are higher.<sup>70</sup> Finally, applying the drug soon after laser treatment increases drug absorption and efficacy. Systematic reporting of LADD parameters may facilitate replication of successful treatments as well as more precise adjustment of treatment parameters if required.

## III. Optimization of Drug Delivery

**Recommendation 8.** We suggest that drug delivery via LADD may be increased by using heat, pressure, occlusion, and/or low viscosity drug formulations (level of evidence: low; recommendation: conditional). | To increase drug absorption and efficacy, the treating physician may use techniques such as heat, pressure, or occlu-



Table 3. Laser-Assisted Drug Delivery (LADD) Indications Discussed by Guideline Panel Members

Indications	Examples of topical agents administered with LADD <sup>a</sup>	GRADE rating	
		Evidence <sup>b</sup>	Strength <sup>b</sup>
Actinic keratoses	Methylaminolevulinate; aminolevulinic acid; calcipotriol	Moderate	Strong
Squamous cell carcinoma in situ	Fluorouracil; methylaminolevulinate; aminolevulinic acid	Moderate	Strong
Actinic cheilitis	Methylaminolevulinate; aminolevulinic acid	Moderate	Strong
Analgesia	Lidocaine	Moderate	Strong
Hypertrophic scars	Verapamil hydrochloride; 5-fluorouracil; corticosteroids	Low	Conditional
Keloidal scars	Verapamil hydrochloride; 5-fluorouracil; corticosteroids	Low	Conditional
Basal cell carcinoma	Fluorouracil; methyl aminolevulinate	Panel did not offer recommendation	
Hypopigmented scars	Bimatoprost; latanoprost		
Onychomycosis	Tazarotene; tioconazole; amorolfine lacquer		
Melasma	Hydroquinone; tranexamic acid		
Acne vulgaris	Methyl aminolevulinate		
Macular amyloid	Vitamin C; corticosteroids		
Vitiligo	Betamethasone		
Condyloma	5-aminolevulinic acid		
Palmar hyperhidrosis	Onabotulinum toxin A		
Psoriasis	Calcipotriol		
Skin rejuvenation	Aminolevulinic acid		
Rhytids	Poly-L-lactic acid		
Androgenetic alopecia	Minoxidil; minoxidilalane		
Morphea or scleroderma	Poly-L-lactic acid		
Sclerodermoid graft-vs-host disease	Clobetasol		
Local inflammatory arthritis	Diclofenac		
Angiofibroma	Rapamycin		

Abbreviation: GRADE, Grading of Recommendations Assessment, Development and Evaluation.

<sup>a</sup> These are provided for illustrative purposes and are based on published reports.<sup>14-66,68,69</sup>

<sup>b</sup> Level of evidence and strength of recommendation were determined by the guideline panel for the specific indication, but not necessarily for a particular technique or topical agent.

sion after medication application.<sup>77-82</sup> Regarding the drug vehicle, low viscosity formulations, such as aqueous solutions, lotions, or gels, appear to be more effective at filling laser channels, accelerating medication delivery. However, because of the prolonged contact time, occlusion, and hydration afforded by these vehicles, high viscosity formulations, such as creams or ointments, may be preferred.<sup>7</sup> Ultimately, the techniques used to increase drug absorption should be selected based on the underlying disease being treated, treatment location, and patient considerations.

**Recommendation 9.** We suggest that AF laser settings be selected to ensure that the expected channel diameter is greater than the diameter of the particle being delivered (level of evidence: low; recommendation: conditional). | Ensuring that the expected channel diameter is greater than the diameter of the particle being delivered may improve drug penetration. Although the molecular weight of a drug is unlikely to limit its ability to penetrate through a channel created by laser, penetrance may be limited by the effective particle size, particularly if the drug is delivered by a polymer, microsphere, liposome, nanoparticle, or similar means. No specific recommendations were made regarding channel depth, which depends on fluence, and describes how deeply ablated laser channels extend into the skin. Theoretically, the greater the depth, the more extensively the drug being delivered may penetrate, although in practice greater penetration depth does not necessarily improve absorption. However, hydrophilic, and hydrophobic substances react differently to channel depth. For hydrophilic medications, deeper channels may allow for increased drug penetration. Ultimately, chan-

nel diameter and depth should complement the drug in question as well as the disease being treated.<sup>69,82</sup>

**Recommendation 10.** We suggest that cold, nonhollow bore microneedling (without heat/radiofrequency) or radiofrequency microneedling may be alternative modalities to laser for drug delivery (level of evidence: low; recommendation: conditional). | Nonlaser modalities, such as cold nonhollow bore microneedling or insulated or non-insulated radiofrequency microneedling, may also be used for drug delivery.<sup>83</sup> These approaches may be helpful for patients who decline laser, or in whom laser is contraindicated. Further research may clarify the safety and efficacy of these treatment modalities and how they enable drug penetration. Microneedles can be of various bores and lengths, with or without insulation or radiofrequency energy, and hence, may behave differently. Although a recent study using optical coherence tomography found that microneedling and radiofrequency microneedling did not create observable cutaneous channels,<sup>84</sup> other recent research suggests that in some cases microneedling may facilitate increased penetration and greater lateral extension of the drug as compared with AF laser.<sup>83</sup>

#### IV. Safety Considerations

**Recommendation 11.** We recommend that physicians using LADD appreciate that there is a certain unpredictability of response and tissue levels of drug owing to variable pharmacokinetics (level of evidence: moderate; recommendation: strong). | Overall, LADD is a safe and effective procedure. Adverse events, when they occur, are

most often transient and mild (eg, crusting, erythema, postinflammatory hyperpigmentation, and burning sensation). However, we caution laser surgeons that there is a degree of unpredictability of response and drug tissue levels owing to variable pharmacokinetics when drugs are delivered through the skin with laser or other energy-based devices.<sup>70</sup> Additionally, there may be a slightly increased risk of drug-related local adverse events compared with administration of the same medication without energy-based devices.

**Recommendation 12.** We recommend that physicians using LADD be cautious because systemic adverse effects owing to inadvertent systemic delivery of medications are a possibility (level of evidence: moderate; recommendation: strong). | Theoretically, as with any parenteral medication, systemic adverse events are a possibility in LADD. To minimize risk, small volumes should be used (commonly 1-2 mL). A detailed past medical history, including an updated medication list and allergies, should be obtained before treatment.

**Recommendation 13.** We recommend LADD be performed with appropriate eye protection (appropriate for the laser platform), surgical masks, and gloves (level of evidence: moderate; recommendation: strong), and suggest using a smoke evacuator, particularly with AF devices (level of evidence: low; recommendation: conditional). | When performing LADD, we recommend that the laser surgeon wear appropriate, device-specific protective equipment, ie, eye protection specific to the laser, a surgical mask, and surgical gloves. For AFL, we suggest that the surgeon consider the use of a smoke evacuator. Additionally, when treating viral lesions, the surgeon may consider wearing an N95 mask to address the risk of acquired laryngeal papillomatosis.

**Recommendation 14.** We suggest LADD only be used with medication formulations approved by a national regulatory authority for parenteral injection (level of evidence: low; recommendation: conditional). | Only medications approved by the appropriate regulatory authority (eg, US Food and Drug Administration) for injection into the skin, subcutaneous tissue, or intravascular space should be used for LADD. Although necessary, such approval may be insufficient to ensure safety (eg, phenytoin approved for IV use may cause tissue necrosis when it penetrates deep into the skin). Medications indicated only for topical use, such as many cosmeceuticals, moisturizers, topical corticosteroids, topical antibiotics, and antiseptics, and many other over-the-counter and prescription medica-

tions should not be delivered with laser as they may induce sensitivity reactions, granulomas, infections, and systemic adverse reactions.

## V. Prophylaxis for Bacterial, Viral, and Fungal Infections

**Recommendation 15.** We suggest use of the following prophylaxis regimens for AF and NAF LADD in otherwise healthy adults, pediatric patients, and patients who are immunosuppressed: antibiotic prophylaxis is *not* recommended when treating areas other than where wound healing might be impaired (eg, genitalia, lower legs); antiviral prophylaxis is recommended when LADD is used on the face or genitalia; and antifungal prophylaxis is *not* recommended (level of evidence: low; recommendation: conditional). | Antibacterial prophylaxis should be reserved for sites with a high possibility of poor wound healing, such as genitalia or lower legs. Antiviral prophylaxis should be offered when treating the face or genitalia, regardless of herpes simplex virus history. Based on limited evidence, antifungal prophylaxis is typically not needed. Data were insufficient to recommend alterations of prophylaxis regimen based on patient age or immunosuppression status.

## Limitations

Laser-assisted drug delivery is a novel technology that is rapidly evolving. There may yet be substantial changes over time in how LADD is routinely performed and, consequently, in its safety and effectiveness. Therefore, the current guidelines may need to be revised in the future. Although LADD is a relatively new technology, the current guidelines are important to ensure that practitioners and patients have an understanding of how it should be performed and what are its benefits and limitations. These guidelines may also assist in identifying areas of uncertainty to address with future research.

## Conclusions

The findings of this systematic review and Delphi consensus study suggest that LADD can be a safe and effective treatment for various indications. As the standard of care continues to shift toward minimally invasive and individualized methods of drug delivery, LADD will play an important role. Future research will bolster understanding of these promising procedures and how they may be further optimized for clinical effectiveness while maintaining a high level of therapeutic safety.

## ARTICLE INFORMATION

**Accepted for Publication:** June 17, 2022.

**Published Online:** August 17, 2022.

doi:10.1001/jamadermatol.2022.3234

**Author Affiliations:** Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Labadie, Ibrahim, Worley, Kang, Christensen, Poon, Alam); Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois (Rakita, Rigali); SkinCare Physicians, Chestnut Hill, Massachusetts (Arndt, Dover); Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island (Arndt,

Dover); Main Line Center for Laser Surgery, Ardmore, Pennsylvania (Bernstein); Ronald O. Perleman Department of Dermatology, New York University School of Medicine, New York (Brauer); Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Chandra); Department of Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Didwania); Boston Center for Facial Rejuvenation, Boston, Massachusetts (DiGiorgio); Shriners Hospital for Children—Boston, Harvard Medical School, Boston, Massachusetts (Donelan); Massachusetts General Hospital, Harvard Medical School, Boston,

Massachusetts (Donelan); Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut (Dover, Suozzi); College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates (Galadari); Laser & Skin Surgery Center of New York, New York (Geronemus); Cosmetic Laser Dermatology, West Dermatology Company, San Diego, California (Goldman); Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark (Haedersdal); Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston (Haedersdal); Departments of Dermatology and Otolaryngology, St Louis University—Laser and



Dermatologic Surgery Center, St Louis, Missouri (Hruza); Connecticut Skin Institute, Stamford, Connecticut (Ibrahimi); New York Laser & Skin Care, New York (Kauvar); New York University Grossman School of Medicine, New York, New York (Kauvar); Department of Dermatology, University of California Irvine School of Medicine, Irvine (Kelly); Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania (Krakowski); Department of Dermatology, Mayo Clinic, Rochester, Minnesota (Miest); Department of Dermatology, Michigan Medicine, University of Michigan, Ann Arbor (Orringer); Department of Dermatology, Henry Ford Hospital, Detroit, Michigan (Ozog); Scripps Clinic, San Diego, California (Ross); Veterans Affairs San Diego Healthcare System and University of California, San Diego, California (Shumaker); Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (Sobanko); Gateway Aesthetic Institute & Laser Center, Salt Lake City, Utah (Taylor); Department of Dermatology, School of Medicine, Stanford University, Stanford, California (Teng); Coronado Dermatology, Lanoi Cosmetic Dermatology, San Diego, California (Uebelhoefer); Miami Dermatology and Laser Institute, Miami, Florida (Waibel); Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston (Wanner); Section of Cutaneous Surgery, Northwestern Medical Group, Chicago, Illinois (Ratchev); Galter Health Sciences Library & Learning Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Miller); Department of Otolaryngology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Alam); Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Alam); Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (Alam).

**Author Contributions:** Dr Alam had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Labadie and Ms Ibrahim contributed equally as co-first authors.

**Concept and design:** Labadie, Ibrahim, Worley, Galadari, Geronemus, Ibrahimi, Kauvar, Ozog, Suozzi, Taylor, Uebelhoefer, Waibel, Poon, Alam. **Acquisition, analysis, or interpretation of data:** Labadie, Ibrahim, Worley, Kang, Rakita, Rigali, Arndt, Bernstein, Brauer, Chandra, Didwania, DiGiorgio, Donelan, Dover, Galadari, Geronemus, Hruza, Kauvar, Kelly, Krakowski, Miest, Orringer, Ozog, Ross, Shumaker, Sobanko, Suozzi, Teng, Uebelhoefer, Waibel, Wanner, Ratchev, Christensen, Miller, Alam.

**Drafting of the manuscript:** Labadie, Ibrahim, Kang, Rigali, Arndt, Bernstein, Kauvar, Krakowski, Suozzi, Waibel, Miller, Alam.

**Critical revision of the manuscript for important intellectual content:** Labadie, Ibrahim, Worley, Kang, Rakita, Bernstein, Brauer, Chandra, Didwania, DiGiorgio, Donelan, Dover, Galadari, Geronemus, Goldman, Haedersdal, Hruza, Ibrahimi, Kauvar, Kelly, Krakowski, Miest, Orringer, Ozog, Ross, Shumaker, Sobanko, Suozzi, Taylor, Teng, Uebelhoefer, Waibel, Wanner, Ratchev, Christensen, Poon, Alam.

**Statistical analysis:** Ibrahim, Worley, Rigali, Alam. **Administrative, technical, or material support:** Labadie, Ibrahim, Kang, Rigali, Galadari, Geronemus, Goldman, Krakowski, Ross, Suozzi,

Uebelhoefer, Waibel, Christensen, Poon, Miller, Alam. **Supervision:** Labadie, Chandra, Galadari, Ibrahimi, Sobanko, Suozzi, Uebelhoefer, Alam.

**Other-provided data:** DiGiorgio.

**Other-systematic literature search:** Miller.

**Conflict of Interest Disclosures:** Dr Worley reported consulting fees from Castle Biosciences and serving on the editorial board of the *Journal of the American Academy of Dermatology* outside of the submitted work. Dr Bernstein reported equity holdings in Candela, Joylux, Novoxel, Acclaro, OnSite Waste, and Cynosure; consulting fees from Cynosure and Acclaro; and funding from Candela, Acclaro, Novoxel, Cynosure, and Merz, during the conduct of the study. Dr DiGiorgio reported equity and research conducted for Quthero, outside the submitted work. Dr Dover reported grants from Allergan/AbbVie, Cutera, Cynosure, Follica, Bausch & Lomb, Syneron Candela, Lumenis, Revance, Zeltiq (Allergan); equity in Vyome and Controversies Medical Meeting; consulting and advisory board membership for Allergan/AbbVie, Cynosure, Cutera, Follica, Zeltiq, Bausch & Lomb, Revance, Vyome, Follica, L'Oreal, and Allergan/Soliton; and is an UpToDate contributing editor, all outside of the submitted work. Dr Geronemus reported medical advisory board membership for Cytrelis, Lutronic, and Solta, and being an investigator for Cytrelis, Lutronic, Sciton, and Solta, outside of the submitted work. Dr Haedersdal reported grants from Leo Pharma, Lutronic, Mirai Medical, Studies&Me, and Venus Concept and speaking engagements with Galderma Nordic outside of the submitted work. Dr Ibrahim reported medical advisory board membership for Lutronic and Cutera; receiving speaking honoraria from Lutronic; and equity holdings in Johnson & Johnson, Regeneron, Editas Medicine, Intellia Therapeutics, Crispr Therapeutics, Revance Therapeutics, AbbVie, Pfizer, Accure Acne, and AVAVA, outside of the submitted work. Dr Kelly reported conducting research with and receiving equipment from Sciton; consulting fees from Sciton, IQVI, and FDZJ; grants from Biophotas, Michaelson Diagnostics, and Orlucant; and board membership for the American Society for Laser Medicine and Surgery, all outside of the submitted work; and provided research devices for the clinic during the conduct of the study. Dr Waibel reported conducting research with AbbVie, ArgenX, AstraZeneca, Avita Medical, Dermira, Eli Lilly, Novartis, Olix Pharmaceuticals, Pfizer, RegenX, and UCB Biopharma; consulting fees from Avita Medical, Biofrontera, Candela, Cytrelis Biosystems, and RegenX; advisory board membership with Candela, Cytrelis Biosystems, Dominion Aesthetics, and Sciton; speaking honoraria from Candela, Eli Lilly, Novartis, and Ortho Dermatologics, outside of the submitted work. Dr Wanner reported a grant and equipment from Bausch Health, outside of the submitted work. Dr Wanner reported grants from Bausch Health; consulting fees from Nu Skin Scientific Advisory Board; and equity in Clarity Cosmetics and Lightwater Biosciences, outside of the submitted work. Dr Brauer reported honoraria and consulting fees from Solta and Cynosure, outside of the submitted work. Dr Ross reported advisory board membership for Accure, Lumemis, Candela, and Cynosure; grants from Lumemis, LuTronic, and Cynosure; consulting fees from Sentient, AMP, Pulsed Biosciences, Candela, Alma, and Cartessa Aesthetics, all outside the submitted work. Dr Shumaker reported travel fees and honoraria

from Lumenis outside the submitted work. No other disclosures were reported.

**Funding/Support:** This study was partially supported by unrestricted research funding from the Section of Cutaneous Surgery of the Department of Dermatology at Northwestern University.

**Role of the Funder/Sponsor:** Northwestern University had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the US Department of Veterans Affairs or the US Government.

## REFERENCES

1. Hauck WW. Bioequivalence studies of topical preparations: statistical considerations. *Int J Dermatol*. 1992;31(suppl 1):29-33. doi:10.1111/j.1365-4362.1992.tb04010.x
2. Jacques SL, McAuliffe DJ, Blank IH, Parrish JA. Controlled removal of human stratum corneum by pulsed laser. *J Invest Dermatol*. 1987;88(1):88-93. doi:10.1111/1523-1747.ep12465112
3. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med*. 2004;34(5):426-438. doi:10.1002/lsm.20048
4. Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG, Tam J, Anderson RR. Fractional CO(2) laser-assisted drug delivery. *Lasers Surg Med*. 2010;42(2):113-122. doi:10.1002/lsm.20860
5. Yu J, Kalaria DR, Kalia YN. Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. *J Control Release*. 2011;156(1):53-59. doi:10.1016/j.jconrel.2011.07.024
6. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. *J Am Acad Dermatol*. 2008;58(5):719-737. doi:10.1016/j.jaad.2008.01.003
7. Wenande E, Anderson RR, Haedersdal M. Fundamentals of fractional laser-assisted drug delivery: an in-depth guide to experimental methodology and data interpretation. *Adv Drug Deliv Rev*. 2020;153:169-184. doi:10.1016/j.addr.2019.10.003
8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med*. 2021;18(3):e1003583. doi:10.1371/journal.pmed.1003583
9. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919. doi:10.1136/bmj.i4919
10. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the *Journal of Clinical Epidemiology*. *J Clin Epidemiol*. 2011;64(4):380-382. doi:10.1016/j.jclinepi.2010.09.011
11. Dalkey N. The Delphi method: an experimental study of group opinion. *Futures*. 1969;1:408-426. doi:10.1016/S0016-3287(69)80025-X
12. Gustafson DH, Shukla RK, Delbecq A, Walster GW. A comparative study of differences in

subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. *Organ Behav Hum Perform*. 1973;9:280-291. doi:10.1016/0030-5073(73)90052-4

13. Waibel JS, Mi QS, Ozog D, et al. Laser-assisted delivery of vitamin C, vitamin E, and ferulic acid formula serum decreases fractional laser postoperative recovery by increased beta fibroblast growth factor expression. *Lasers Surg Med*. 2016; 48(3):238-244. doi:10.1002/lsm.22448
14. Alexiades M. Randomized, double-blind, split-face study evaluating fractional ablative Erbium:YAG laser-mediated trans-epidermal delivery of cosmetic actives and a novel acoustic pressure wave ultrasound technology for the treatment of skin aging, melasma, and acne scars. *J Drugs Dermatol*. 2015;14(11):1191-1198.
15. Ruiz-Rodriguez R, López L, Candelas D, Zelickson B. Enhanced efficacy of photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. *J Drugs Dermatol*. 2007;6(8):818-820.
16. Ibrahim O, Ionta S, Depina J, Petrelli K, Arndt KA, Dover JS. Safety of laser-assisted delivery of topical poly-L-lactic acid in the treatment of upper lip rhytides: a prospective, rater-blinded study. *Dermatol Surg*. 2019;45(7):968-974. doi:10.1097/DSS.0000000000001743
17. Cho YR, Seo JW, Kim HJ, Song KH. A comparison of the efficacy of ablative fractional laser-assisted photodynamic therapy according to the density of the ablative laser channel in the treatment of actinic keratosis: A prospective, randomized, controlled trial. *J Am Acad Dermatol*. 2021;85(3):750-752. doi:10.1016/j.jaad.2019.10.037
18. Seo JW, Song KH. Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades III-V skin: A prospective randomized clinical trial. *J Am Acad Dermatol*. 2018;78(4):795-797. doi:10.1016/j.jaad.2017.11.027
19. Togsverd-Bo K, Lei U, Eriksen AM, et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients: a randomized controlled trial. *Br J Dermatol*. 2015; 172(2):467-474. doi:10.1111/bjd.13222
20. Ko DY, Jeon SY, Kim KH, Song KH. Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study. *J Eur Acad Dermatol Venereol*. 2014;28(11):1529-1539. doi:10.1111/jdv.12334
21. Choi SH, Kim KH, Song KH. Efficacy of ablative fractional laser-assisted photodynamic therapy with short-incubation time for the treatment of facial and scalp actinic keratosis: 12-month follow-up results of a randomized, prospective, comparative trial. *J Eur Acad Dermatol Venereol*. 2015;29(8):1598-1605. doi:10.1111/jdv.12953
22. Choi SH, Kim TH, Song KH. Efficacy of iontophoresis-assisted ablative fractional laser photodynamic therapy with short incubation time for the treatment of actinic keratosis: 12-month follow-up results of a prospective, randomized, comparative trial. *Photodiagnosis Photodyn Ther*. 2017;18:105-110. doi:10.1016/j.pdpdt.2017.01.184
23. Vrani F, Sotiriou E, Lazaridou E, et al. Short incubation fractional CO<sub>2</sub> laser-assisted photodynamic therapy vs. conventional

- photodynamic therapy in field-cancerized skin: 12-month follow-up results of a randomized intraindividual comparison study. *J Eur Acad Dermatol Venereol*. 2019;33(1):79-83. doi:10.1111/jdv.15109
24. Song HS, Jung SE, Jang YH, Kang HY, Lee ES, Kim YC. Fractional carbon dioxide laser-assisted photodynamic therapy for patients with actinic keratosis. *Photodermatol Photoimmunol Photomed*. 2015;31(6):296-301. doi:10.1111/phpp.12184
  25. Alexiades M. Randomized, controlled trial of fractional carbon dioxide laser resurfacing followed by ultrashort incubation aminolevulinic acid blue light photodynamic therapy for actinic keratosis. *Dermatol Surg*. 2017;43(8):1053-1064. doi:10.1097/DSS.0000000000001117
  26. Helsing P, Togsverd-Bo K, Veierød MB, Mørk G, Haedersdal M. Intensified fractional CO<sub>2</sub> laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. *Br J Dermatol*. 2013;169(5):1087-1092. doi:10.1111/bjd.12507
  27. Hsu SH, Gan SD, Nguyen BT, Konnikov N, Liang CA. Ablative fractional laser-assisted topical fluorouracil for the treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ: a follow-up study. *Dermatol Surg*. 2016;42(9): 1050-1053. doi:10.1097/DSS.0000000000000814
  28. Ko DY, Kim KH, Song KH. A randomized trial comparing methyl aminolevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. *Br J Dermatol*. 2014;170(1):165-172. doi:10.1111/bjd.12627
  29. Kim HJ, Song KH. Ablative fractional laser-assisted photodynamic therapy provides superior long-term efficacy compared with standard methyl aminolevulinate photodynamic therapy for lower extremity Bowen disease. *J Am Acad Dermatol*. 2018;79(5):860-868. doi:10.1016/j.jaad.2018.05.034
  30. Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. *Lasers Surg Med*. 2008;40(2):153-158. doi:10.1002/lsm.20606
  31. Sung JM, Kim YC. Photodynamic therapy with epidermal ablation using fractional CO<sub>2</sub> laser for treating superficial basal cell carcinoma: a case series. *Photodiagnosis Photodyn Ther*. 2017;19: 202-204. doi:10.1016/j.pdpdt.2017.06.009
  32. Lippert J, Smucler R, Vlk M. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. *Dermatol Surg*. 2013;39(8): 1202-1208. doi:10.1111/dsu.12242
  33. Choi SH, Kim KH, Song KH. Efficacy of ablative fractional laser-assisted photodynamic therapy for the treatment of actinic cheilitis: 12-month follow-up results of a prospective, randomized, comparative trial. *Br J Dermatol*. 2015;173(1):184-191. doi:10.1111/bjd.13542
  34. Haak CS, Togsverd-Bo K, Thaysen-Petersen D, et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial. *Br J Dermatol*. 2015;172(1): 215-222. doi:10.1111/bjd.13166
  35. Choi SH, Kim KH, Song KH. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment

- option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. *J Eur Acad Dermatol Venereol*. 2016;30(5):783-788. doi:10.1111/jdv.13453
36. Genou E, Verheire B, Ongenae K, et al. Laser-assisted photodynamic therapy for superficial basal cell carcinoma and Bowen's disease: a randomized inpatient comparison between a continuous and a fractional ablative CO<sub>2</sub> laser mode. *J Eur Acad Dermatol Venereol*. 2018;32(11): 1897-1905. doi:10.1111/jdv.14989
  37. Seo JW, Kim HJ, Song KH. A comparison of the efficacy of ablative fractional laser-assisted photodynamic therapy according to ablative depth for actinic keratosis: a single-blinded, randomized, comparative, prospective study. *J Am Acad Dermatol*. 2019;81(2):636-638. doi:10.1016/j.jaad.2019.01.033
  38. Singer AJ, Weeks R, Regev R. Laser-assisted anesthesia reduces the pain of venous cannulation in children and adults: a randomized controlled trial. *Acad Emerg Med*. 2006;13(6):623-628. doi:10.1197/j.aem.2006.01.016
  39. Koh JL, Harrison D, Swanson V, Norvell DC, Coomber DC. A comparison of laser-assisted drug delivery at two output energies for enhancing the delivery of topically applied LMX-4 cream prior to venipuncture. *Anesth Analg*. 2007;104(4):847-849. doi:10.1213/01.ane.0000257925.36641.9e
  40. Meesters AA, Bakker MM, de Rie MA, Wolkerstorfer A. Fractional CO<sub>2</sub> laser assisted delivery of topical anesthetics: A randomized controlled pilot study. *Lasers Surg Med*. 2016;48(2): 208-211. doi:10.1002/lsm.22376
  41. Meesters AA, Nieboer MJ, Kezic S, de Rie MA, Wolkerstorfer A. Parameters in fractional laser assisted delivery of topical anesthetics: role of laser type and laser settings. *Lasers Surg Med*. 2018;50 (8):813-818. doi:10.1002/lsm.22936
  42. Shapiro H, Harris L, Hetzel FW, Bar-Or D. Laser assisted delivery of topical anesthesia for intramuscular needle insertion in adults. *Lasers Surg Med*. 2002;31(4):252-256. doi:10.1002/lsm.10101
  43. Baron ED, Harris L, Redpath WS, et al. Laser-assisted penetration of topical anesthetic in adults. *Arch Dermatol*. 2003;139(10):1288-1290. doi:10.1001/archderm.139.10.1288
  44. Yun PL, Tachihara R, Anderson RR. Efficacy of erbium:yttrium-aluminum-garnet laser-assisted delivery of topical anesthetic. *J Am Acad Dermatol*. 2002;47(4):542-547. doi:10.1067/mjd.2002.124819
  45. Tian T, Luo Y, Jiang T, et al. Clinical effect of ablative fractional laser-assisted topical anesthesia on human skin: A randomized pilot study. *J Cosmet Laser Ther*. 2016;18(7):409-412. doi:10.1080/14764172.2016.1197404
  46. Sabry HH, Abdel Rahman SH, Hussein MS, Sanad RR, Abd El Azeiz TA. The efficacy of combining fractional carbon dioxide laser with verapamil hydrochloride or 5-fluorouracil in the treatment of hypertrophic scars and keloids: a clinical and immunohistochemical study. *Dermatol Surg*. 2019;45(4):536-546. doi:10.1097/DSS.0000000000001726
  47. Tawfik AA, Fathy M, Badawi A, Abdallah N, Shokeir H. Topical 5 fluorouracil cream vs combined 5 fluorouracil and fractional erbium YAG laser for treatment of severe hypertrophic scars. *Clin Cosmet Investig Dermatol*. 2019;12:173-180. doi:10.2147/CCID.S191137

48. Waibel JS, Rudnick A, Arheart KL, Nagrani N, Gonzalez A, Gianatasio C. Re-pigmentation of hypopigmentation: fractional lasers vs laser-assisted delivery of bimatoprost vs epidermal melanocyte harvesting system. *J Drugs Dermatol*. 2019;18(11):1090-1096.
49. Park JH, Chun JY, Lee JH. Laser-assisted topical corticosteroid delivery for the treatment of keloids. *Lasers Med Sci*. 2017;32(3):601-608. doi:10.1007/s10103-017-2154-5
50. Siadat AH, Rezaei R, Asilian A, et al. Repigmentation of hypopigmented scars using combination of fractionated carbon dioxide laser with topical latanoprost vs. fractionated carbon dioxide laser alone. *Indian J Dermatol*. 2015;60(4):364-368. doi:10.4103/0019-5154.160481
51. Waibel JS, Wulkan AJ, Shumaker PR. Treatment of hypertrophic scars using laser and laser assisted corticosteroid delivery. *Lasers Surg Med*. 2013;45(3):135-140.
52. Abd El-Aal EB, Abdo HM, Ibrahim SM, Eldestawy MT. Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis. *J Dermatolog Treat*. 2019;30(3):277-282. doi:10.1080/09546634.2018.1509046
53. de Oliveira GB, Antonio JR, Antonio CR, Tomé FA. The association of fractional CO<sub>2</sub> laser 10.600nm and photodynamic therapy in the treatment of onychomycosis. *An Bras Dermatol*. 2015;90(4):468-471. doi:10.1590/abd1806-4841.20153588
54. Koren A, Salameh F, Sprecher E, Artzi O. Laser-assisted photodynamic therapy or laser-assisted amorphine lacquer delivery for treatment of toenail onychomycosis: an open-label comparative study. *Acta Derm Venereol*. 2018;98(4):467-468. doi:10.2340/00015555-2874
55. Badawi AM, Osman MA. Fractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery of hydroquinone in the treatment of melasma. *Clin Cosmet Investig Dermatol*. 2018;11:13-20. doi:10.2147/CCID.S147413
56. Sobhi RM, Sharaoui I, El Nabarawy EA, El Nemr Esmail RS, Hegazy RA, Aref DHF. Comparative study of fractional CO<sub>2</sub> laser and fractional CO<sub>2</sub> laser-assisted drug delivery of topical steroid and topical vitamin C in macular amyloidosis. *Lasers Med Sci*. 2018;33(4):909-916. doi:10.1007/s10103-018-2457-1
57. Liu L, Wu Y, Zhang J, et al. Ablative fractional CO<sub>2</sub> laser aided delivery of long-acting glucocorticoid in the treatment of acral vitiligo: a multicenter, prospective, self-bilateral controlled study. *J Dermatolog Treat*. 2019;30(4):320-327. doi:10.1080/09546634.2018.1509048
58. Szeimies R-M, Schleyer V, Moll I, Stocker M, Landthaler M, Karrer S. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. *Dermatol Surg*. 2009;35(5):757-764. doi:10.1111/j.1524-4725.2009.01125.x
59. Issa MC, Torreão PS, Boechat M, Luiz R. Early investigations in drug delivery of onabotulinum toxin A using combined fractional ablative laser with impact ultrasound vs. injections of onabotulinum toxin A for palmar hyperhidrosis: a right-left comparison trial. *Br J Dermatol*. 2018;179(5):1168-1169. doi:10.1111/bjd.16781
60. Li R, Zhou J, Su H, et al. 2940-nm Er:YAG fractional laser enhanced the effect of topical drug for psoriasis. *Lasers Med Sci*. 2017;32(6):1393-1397. doi:10.1007/s10103-017-2259-x
61. Croix J, Burge S, Chwalek J, Gmyrek R, Chapas A. Split-sided chest study of skin rejuvenation comparing low-energy, 1927-nm thulium fractional laser treatment prior to photodynamic therapy versus photodynamic therapy alone. *Lasers Surg Med*. 2020;52(1):53-60. doi:10.1002/lsm.23178
62. Hendel K, Mogensen M, Wenande E, Dierickx C, Haedersdal M, Togsverd-Bo K. Fractional 1927 nm thulium laser plus photodynamic therapy compared and combined for photodamaged décolleté skin: a side-by-side randomized controlled trial. *Lasers Surg Med*. 2020;52(1):44-52. doi:10.1002/lsm.23194
63. Kim TI, Ahn HJ, Kang IH, Jeong KH, Kim NI, Shin MK. Nonablative fractional laser-assisted daylight photodynamic therapy with topical methyl aminolevulinate for moderate to severe facial acne vulgaris: results of a randomized and comparative study. *Photodermatol Photoimmunol Photomed*. 2017;33(5):253-259. doi:10.1111/phpp.12312
64. Wanitphakdeedecha R, Sy-Alvarado F, Patthamalai P, Techapichetvanich T, Eimpunth S, Manuskiatti W. The efficacy in treatment of facial melasma with thulium 1927-nm fractional laser-assisted topical tranexamic acid delivery: a split-face, double-blind, randomized controlled pilot study. *Lasers Med Sci*. 2020;35(9):2015-2021. doi:10.1007/s10103-020-03045-8
65. Massaki AB, Fati SG, Fitzpatrick R. Repigmentation of hypopigmented scars using an erbium-doped 1,550-nm fractionated laser and topical bimatoprost. *Dermatol Surg*. 2012;38(7 Pt 1):995-1001. doi:10.1111/j.1524-4725.2012.02389.x
66. Mercuri SR, Brianti P, Foti A, Bartolucci M, Dattola A, Nisticò SP. Penile lichen sclerosis treated with 1927 nm thulium fiber laser and photodynamic therapy: a new possible therapeutic approach. *Photomed Laser Surg*. 2018;36(6):333-336. doi:10.1089/pho.2017.4386
67. US Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. *Clinical Practice Guidelines We Can Trust*. National Academies Press; 2011.
68. Labadie JG, Kosche C, Kylo R, et al. Fractional CO<sub>2</sub> laser for the treatment of sclerodermatous cGVHD. *J Cosmet Laser Ther*. 2020;22(1):49-51. doi:10.1080/14764172.2019.1710537
69. Rkein A, Ozog D, Waibel JS. Treatment of atrophic scars with fractionated CO<sub>2</sub> laser facilitating delivery of topically applied poly-L-lactic acid. *Dermatol Surg*. 2014;40(6):624-631.
70. Ibrahim O, Wenande E, Hogan S, Arndt KA, Haedersdal M, Dover JS. Challenges to laser-assisted drug delivery: applying theory to clinical practice. *Lasers Surg Med*. 2018;50(1):20-27. doi:10.1002/lsm.22769
71. Haak CS, Bhayana B, Farinelli WA, Anderson RR, Haedersdal M. The impact of treatment density and molecular weight for fractional laser-assisted drug delivery. *J Control Release*. 2012;163(3):335-341. doi:10.1016/j.jconrel.2012.09.008
72. Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG, Tam J, Anderson RR. Pretreatment with ablative fractional laser changes kinetics and biodistribution of topical 5-aminolevulinic acid (ALA) and methyl aminolevulinate (MAL). *Lasers Surg Med*. 2014;46(6):462-469. doi:10.1002/lsm.22259
73. Haak CS, Christiansen K, Erlandsson AM, et al. Ablative fractional laser enhances MAL-induced PpIX accumulation: Impact of laser channel density, incubation time and drug concentration. *J Photochem Photobiol B*. 2016;159:42-48. doi:10.1016/j.jphotobiol.2016.03.021
74. Haak CS, Farinelli WA, Tam J, Doukas AG, Anderson RR, Haedersdal M. Fractional laser-assisted delivery of methyl aminolevulinate: impact of laser channel depth and incubation time. *Lasers Surg Med*. 2012;44(10):787-795. doi:10.1002/lsm.22102
75. Wenande E, Olesen UH, Nielsen MM, et al. Fractional laser-assisted topical delivery leads to enhanced, accelerated and deeper cutaneous 5-fluorouracil uptake. *Expert Opin Drug Deliv*. 2017;14(3):307-317. doi:10.1080/17425247.2017.1260119
76. Bay C, Lerche CM, Ferrick B, Philipsen PA, Togsverd-Bo K, Haedersdal M. Comparison of physical pretreatment regimens to enhance protoporphyrin IX uptake in photodynamic therapy: a randomized clinical trial. *JAMA Dermatol*. 2017;153(4):270-278. doi:10.1001/jamadermatol.2016.5268
77. Zaleski-Larsen LA, Fati SG. Laser-assisted drug delivery. *Dermatol Surg*. 2016;42(8):919-931. doi:10.1097/DSS.0000000000000556
78. Braun SA, Schrupp H, Bühren BA, Homey B, Gerber PA. Laser-assisted drug delivery: mode of action and use in daily clinical practice. *J Dtsch Dermatol Ges*. 2016;14(5):480-488. doi:10.1111/ddg.12963
79. Ali FR, Al-Niaimi F. Laser-assisted drug delivery in dermatology: from animal models to clinical practice. *Lasers Med Sci*. 2016;31(2):373-381. doi:10.1007/s10103-015-1853-z
80. Nguyen BT, Gan SD, Konnikov N, Liang CA. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ on the trunk and extremities with ablative fractional laser-assisted delivery of topical fluorouracil. *J Am Acad Dermatol*. 2015;72(3):558-560. doi:10.1016/j.jaad.2014.11.033
81. Cavalié M, Sillard L, Montaudie H, Bahadoran P, Lacour JP, Passeron T. Treatment of keloids with laser-assisted topical steroid delivery: a retrospective study of 23 cases. *Dermatol Ther*. 2015;28(2):74-78. doi:10.1111/dth.12187
82. Bachhav YG, Heinrich A, Kalia YN. Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technology. *Eur J Pharm Biopharm*. 2013;84(2):355-364. doi:10.1016/j.ejpb.2012.11.018
83. Chung HJ, Cheng J, Gonzalez M, Al-Janahi S. Factors affecting depth of penetration in microneedling- and laser-assisted drug delivery: the importance of timing of topical application. *Dermatol Surg*. 2020;46(12):e146-e153. doi:10.1097/DSS.0000000000002381
84. Wang JV, Mehrabi JN, Zachary CB, Geronemus RG. Evaluation of device-based cutaneous channels using optical coherence tomography: impact for topical drug delivery. *Dermatol Surg*. 2022;48(1):120-125. doi:10.1097/DSS.0000000000003275